Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis

Cochrane Database of Systematic Reviews

Volumn 2020, Issue 8, 2020, Pages

  Murray, Alistair ^a   Nguyen, Tran M ^b   Parker, Claire E ^b   Feagan, Brian G ^b,c   MacDonald, John K ^c  

^a WESTERN UNIVERSITY   (Canada)

^b ROBARTS RESEARCH INSTITUTE   (Canada)

^c UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

MESALAZINE; PLACEBO; SALAZOSULFAPYRIDINE; AMINOSALICYLIC ACID DERIVATIVE; NONSTEROID ANTIINFLAMMATORY AGENT;

ABDOMINAL PAIN; ADVERSE EVENT; ARTICLE; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPEPSIA; ENDOSCOPY; FLATULENCE; FOLLOW UP; HEADACHE; HUMAN; MAINTENANCE THERAPY; MEDICATION COMPLIANCE; NAUSEA; PATIENT COMPLIANCE; PRIORITY JOURNAL; REMISSION; SYSTEMATIC REVIEW; TREATMENT DURATION; ULCERATIVE COLITIS; DRUG ADMINISTRATION; MAINTENANCE CHEMOTHERAPY; META ANALYSIS; ORAL DRUG ADMINISTRATION; PATIENT DROPOUT; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; STATISTICAL BIAS;

ADMINISTRATION, ORAL; AMINOSALICYLIC ACIDS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BIAS; COLITIS, ULCERATIVE; DRUG ADMINISTRATION SCHEDULE; HUMANS; MAINTENANCE CHEMOTHERAPY; MEDICATION ADHERENCE; MESALAMINE; PATIENT DROPOUTS; PLACEBOS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE; REMISSION INDUCTION; SULFASALAZINE;

EID: 85089949392     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD000544.pub5     Document Type: Article

References (189)

1. Andreoli A, Cosintino R, Trotti R, Berri F, Prantera C. 5-aminosalicylic acid (5-ASA) versus salazopirin (SASP) in the oral treatment of active ulcerative colitis (UC) and in remission. Clinical Controversies in Inflammatory Bowel Disease 1987:170. x-wiley/crsRef/14401917
2. Ardizzone S, Petrillo M, Molteni P, Desideri S, Bianchi Porro G. Coated oral 50 aminosalicylic acid (Claversal) is equivalent to sulfasalazine for remission maintenance in ulcerative colitis. Journal of Clinical Gastroenterology 1995;21:287-9. x-wiley/crsRef/14401919
3. Bianchi Porro GB, Ardizzone S, Fasoli R, Petrillo M, Desideri S. Comparison of mesalazine with sulphasalazine in prophylactic treatment of ulcerative colitis. Gut 1989;30:A1467. x-wiley/crsRef/14401920
4. Ardizzone S, Petrillo M, Imbesi V, Cerutti R, Bollani S, Bianchi Porro G. Is maintenance therapy always necessary for patients with ulcerative colitis? Alimentary Pharmacology and Therapeutics 1999;13:373-9. x-wiley/crsRef/14401922
5. Courtney MG, Nunes DP, Bergin CF, O'Driscoll M, Trimble V, Keeling PW, et al. Randomised comparison of olsalazine and mesalazine in prevention of relapses in ulcerative colitis. Lancet 1992;339:1279-81. x-wiley/crsRef/14401924
6. Courtney MG, Nunes DP, Bergin CF. Prospective randomized trial of mesalazine versus olsalazine in ulcerative colitis. Gastroenterology 1990;98(5 Part 2):A165. x-wiley/crsRef/14401925
7. D'Haens G, Sandborn WJ, Barrett K, Hodgson I, Streck P. Once-daily MMX® mesalamine for endoscopic maintenance of remission of ulcerative colitis. American Journal of Gastroenterology 2012;107(7):1064-77. x-wiley/crsRef/14401927
8. Deventer SJ, Hommes DW, Roskam-Mul MD, Dekker W, Gasthuis K, Wetzels A, et al. Prospective randomized open label blinded endpoint (PROBE) trial of high versus low dose mesalazine for prevention of relapse in patients with UC in remission. Gastroenterology 2001;120(5 Suppl 1):A454. x-wiley/crsRef/14401929
9. Dew MJ, Harries AD, Evans N, Evans BK, Rhodes J. Maintenance of remission in ulcerative colitis with 5-aminosalicylic acid in high doses by mouth. British Medical Journal 1983;287:23-4. x-wiley/crsRef/14401931
10. Dew MJ, Harries AD, Evans N, Evans BK, Rhodes J. Maintenance of remission in ulcerative colitis with an oral preparation of 5-aminosalicylic acid in high doses. Gut 1983;24(Suppl 10):A983. x-wiley/crsRef/14401932
11. Bokemeyer B, Hommes D, Gill I, Broberg P, Dignass A. Mesalazine in left-sided ulcerative colitis: efficacy analyses from the PODIUM trial on maintenance of remission and mucosal healing. Journal of Crohn's and Colitis 2012;6(4):476-82. x-wiley/crsRef/14401934
12. Dignass A, Bokemeyer B, Mross M, Oudkerk Pool M. Symptom resolution and clinical remission in patients with mild-to-moderate ulcerative colitis: analysis of the PODIUM trial. Journal of Crohn's and Colitis 2013;7:S153-4. x-wiley/crsRef/14401935
13. Dignass A, Bokemeyer B, Stijnen T, Klugmann T, Oudkerk M, Veerman H. Impact of once-daily versus twice-daily mesalazine (Pentasa) on relief of rectal bleeding and stool frequency: results from a multinational randomised controlled trial. In: Canadian Journal of Gastroenterology. Vol. 23. 2009. x-wiley/crsRef/14401936
14. Dignass A, Bokemeyer B, Stijnen T, Tan T, Borner N, Oudkerk Pool M, et al. Safety of once-daily vs twice-daily mesalazine (Pentasa) dosing. Results from a 12-month randomised controlled trial in maintenance of remission of ulcerative colitis. Canadian Journal of Gastroenterology 2009;23:S73. x-wiley/crsRef/14401937
15. Dignass A, Stijnen T, Mross MR, Vermeire S, Veerman H, Bhatt A. Pentasa (mesalazine) once or twice daily for the management of maintenance of remission of ulcerative colitis: demographic and baseline data of a 12 month single blind randomised controlled trial. Gastroenterology 2007;132(4 Suppl 1):A502-3. x-wiley/crsRef/14401938
16. Dignass A, Vermeire S, Adamek H, Befrits R, Bokemeyer B, Börner N, et al. Improved remission rates from once- versus twice-daily mesalazine (Pentasa) granules for the maintenance of remission in ulcerative colitis: results from a multinational randomised controlled trial. In: UEGW – Abstract Database. 2007:OP-G-378. x-wiley/crsRef/14401939
17. Dignass AU, Bokemeyer B, Adamek H, Mross M, Vinter-Jensen L, Börner N, et al. Mesalamine once daily is more effective than twice daily in patients with quiescent ulcerative colitis. Clinical Gastroenterology and Hepatology 2009;7(7):762-9. x-wiley/crsRef/14401940
18. Dignass AU, Bokemeyer B, Adamek HE, Mross MR, Vinter-Jensen L, Boerner N, et al. Maintenance therapy with once-daily 2 g mesalazine (Pentasa) treatment improves remission rates in subjects with ulcerative colitis compared to twice daily 1 g mesalazine: data from a randomised controlled trial. Gastroenterology 2008;134(4 Suppl 1):A494. x-wiley/crsRef/14401941
19. Dignass AU, Bokemeyer B, Adamek HE, Mross MR, Vinter-Jensen L, Boerner N, et al. Treatment acceptability in a randomised controlled trial of once-daily or twice-daily mesalazine (Pentasa) for the maintenance of remission in ulcerative colitis. Gastroenterology 2008;134(4 Suppl 1):A495-6. x-wiley/crsRef/14401942
20. Dignass AU, Bokemeyer B, Stijnen T, Veerman H. Impact of once-daily versus twice-daily mesalazine (Pentasa) on relief of rectal bleeding and stool frequency: results from a multinational randomised controlled trial. Gastroenterology 2009;136(5 Suppl 1):A685. x-wiley/crsRef/14401943
21. Dignass AU, Muls V, Silvennoinen J, Pool MO, Befrits R, Broberg P, et al. The PODIUM trial of once-daily versus twice-daily mesalazine dosing in ulcerative colitis: maintenance of mucosal healing. Gastroenterology 2010;1:S520. x-wiley/crsRef/14401944
22. Vermeire S, Befrits R, Bokemeyer B, Gill I, Hommes DW, Broberg P, et al. Efficacy of once-daily versus twice-daily mesalazine (Pentasa): sub-analysis of the left-sided colitis population in the randomised PODIUM trial. Gastroenterology 2010;1:S522. x-wiley/crsRef/14401945
23. Fockens P, Mulder CJ, Ferwada J, Tytgat GN, the Dutch Pentasa Study Group. Relapse prevention of ulcerative colitis: double-blind comparison of 1.5 gram versus 3 gram oral mesalazine (Pentasa). Gastroenterology 1993;104:A701. x-wiley/crsRef/14401947
24. Fockens P, Mulder CJ, Tytgat GN, Blok P, Ferwerda J, Meuwissen SG, et al. Comparison of the efficacy and safety of 1.5 compared with 3.0 g oral slow-release mesalazine (Pentasa) in the maintenance treatment of ulcerative colitis. Dutch Pentasa Study Group. European Journal of Gastroenterology and Hepatology 1995;7(11):1025-30. x-wiley/crsRef/14401948
25. Giaffer MH, Holdsworth CD, Lennard-Jones JE, Rodrigues CA, McIntyre PB, Manjunatha S, et al. Improved maintenance of remission in ulcerative colitis by balsalazide 4 g/day compared with 2 g/day. Alimentary Pharmacology and Therapeutics 1992;6:479-85. x-wiley/crsRef/14401950
26. Gordon GL, Zakko S, Murthy U, Sedghi S, Pruitt R, Barrett AC, et al. Once-daily mesalamine formulation for maintenance of remission in ulcerative colitis. Journal of Clinical Gastroenterology 2016;50(4):318-25. x-wiley/crsRef/14401952
27. Green JR, Swan CH, Rowlinson A, Gibson JA, Brown P, Kerr GD, et al. Short report: comparison of two doses of balsalazide in maintaining ulcerative colitis in remission over 12 months. Alimentary Pharmacology and Therapeutics 1992;6:647-52. x-wiley/crsRef/14401954
28. Green JR, Swan CH, Rowlinson AE, Gibson JA, Brown P, Kerr GD, et al. A three-year prospective study of the maintenance of remission of ulcerative colitis by a new 5-ASA releasing agent, balsalazide. Gastroenterology 1992;102(4 Part 2):A631. x-wiley/crsRef/14401955
29. Green JR, Gibson JA, Kerr GD, Swarbrick ET, Lobo AJ, Holdsworth CD, et al. Maintenance of remission of ulcerative colitis: a comparison between balsalzide 3 g daily and mesalazine 1.2 g daily over 12 months. Alimentary Pharmacology and Therapeutics 1998;12:1207-16. x-wiley/crsRef/14401957
30. Hanauer S, Powers B, Robinson M, Mayle J, Elson C. Maintenance of remission of ulcerative colitis by mesalamine (Asacol) versus placebo. Gastroenterology 1994;106:A696. x-wiley/crsRef/14401959
31. Hanauer SB, Sninsky CA, Robinson M, Powers BJ, McHattie JD, Mayle JE, et al. An oral preparation of mesalamine as long-term maintenance therapy for ulcerative colitis. A randomized, placebo-controlled trial. Annals of Internal Medicine 1996;124:204-11. x-wiley/crsRef/14401960
32. Hawkey CJ, Dube LM, Rountree LV, Linnen PJ, Lancaster JF, the European Zileuton Study Group for Ulcerative Colitis. A trial of zileuton versus mesalazine or placebo in the maintenance of remission of ulcerative colitis. Gastroenterology 1997;112:718-24. x-wiley/crsRef/14401962
33. Hawthorne AB, Stenson R, Gillespie D, Swarbrick ET, Dhar A, Kapur KC, et al. Once daily asacol in maintenance therapy for ulcerative colitis: a one-year singe-blind randomised trial. Gut 2011;60:A37-8. x-wiley/crsRef/14401964
34. Hawthorne AB, Stenson R, Gillespie D, Swarbrick ET, Dhar A, Kapur KC, et al. Once daily mesalazine as maintenance therapy for ulcerative colitis (UC): a one-year single-blind randomised trial. Gastroenterology 2011;140(5 Suppl 1):S65. x-wiley/crsRef/14401965
35. Hawthorne AB, Stenson R, Gillespie D, Swarbrick ET, Dhar A, Kapur KC, et al. One-year investigator-blind randomized multicenter trial comparing Asacol 2.4 g once daily with 800 mg three times daily for maintenance of remission in ulcerative colitis. Inflammatory Bowel Disease 2012;18(10):1885-93. x-wiley/crsRef/14401966
36. Ireland A, Jewell DP. Comparative trial of olsalazine and sulfasalazine for the maintenance treatment of ulcerative colitis (UC). Gastroenterology 1987;92:A1447. x-wiley/crsRef/14401968
37. Ireland A, Mason CH, Jewell DP. Controlled trial comparing olsalazine and sulphasalazine for the maintenance treatment of ulcerative colitis. Gut 1988;29:835-7. x-wiley/crsRef/14401969
38. Jewell DP, Ireland A. Controlled trial comparing olsalazine and sulfasalazine for maintenance treatment of ulcerative colitis. Scandinavian Journal of Gastroenterology. Supplement 1988;148:45-7. x-wiley/crsRef/14401970
39. Ito H, Iida M, Matsumoto T, Suzuki Y, Aida Y, Yoshida T, et al. Direct comparison of two different mesalamine formulations for the maintenance of remission in patients with ulcerative colitis: a double-blind, randomized study. Inflammatory Bowel Diseases 2010;16(9):1575-82. x-wiley/crsRef/14401972
40. Kamm MA, Colombel J, Kornbluth A, Diebold R, Barrett K, Karlstadt RG, et al. A randomized comparison of once- versus twice-daily MMX® mesalamine for the maintenance of remission in mild-to-moderate ulcerative colitis. Gastroenterology 2007;132(4 Suppl 1):A510. x-wiley/crsRef/14401974
41. Kamm MA, Lichtenstein GR, Sandborn WJ, Schreiber S, Lees K, Barrett K, et al. Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis. Gut 2008;57(7):893-902. x-wiley/crsRef/14401975
42. Kamm MA, Schreiber S, Butler T, Barrett K, Stephenson D, Joseph RE. Safety analysis of MMX mesalazine for the maintenance of remission of mild-to-moderate ulcerative colitis: results of 4-month interim data analysis. In: UEGW Abstract Database. 2006:MON-G-230. x-wiley/crsRef/14401976
43. Rubin D, Dubinsky M, Panaccione R, Siegel C, Binion D, Kane S, et al. Ulcerative colitis: patients’ perceptions compared with other chronic diseases. Inflammatory Bowel Diseases 2008;14(S1):S22. x-wiley/crsRef/14401977
44. Sandborn W, Kamm M, Lichtenstein G, Barrett K, Joseph R. MMX™ mesalamine for the maintenance of remission in mild-to-moderate ulcerative colitis. Inflammatory Bowel Diseases 2008;14(S1):S24. x-wiley/crsRef/14401978
45. Kane S, Huo D, Magnanti K. A pilot feasibility study of once daily versus conventional dosing mesalamine for maintenance of ulcerative colitis. Clinical Gastroenterology and Hepatology 2003;1(3):170-3. x-wiley/crsRef/14401980
46. Kane S, Holderman W, Jacques P, Miodek T. Once daily versus conventional dosing of pH-dependent mesalamine long-term to maintain quiescent ulcerative colitis: preliminary results from a randomized trial. Patient Preference and Adherence 2008;2(2):253-8. x-wiley/crsRef/14401982
47. Kiilerich S, Ladefoged K, Rannem T, Ranlov P. Prophylactic effects of olsalazine (OLZ) versus sulfasalazine (SASP) in 12 months' maintenance treatment of ulcerative colitis. Gastroenterology 1991;100(5 Part 2):A220. x-wiley/crsRef/14401984
48. Kiilerich S, Ladefoged K, Rannem T, Ranlov PJ. Prophylactic effects of olsalazine versus sulphasalazine during 12 months maintenance treatment of ulcerative colitis. Danish Olsalazine Study Group. Gut 1992;33:252-5. x-wiley/crsRef/14401985
49. Kruis W, Brandes JW, Schreiber S, Theuer D, Krakamp B, Schutz E. Olsalazine versus mesalazine in the treatment of mild to moderate ulcerative colitis. Alimentary Pharmacology & Therapeutics 1998;12(8):707-15. x-wiley/crsRef/14401987
50. Kruis W, Judmaier G, Kayasseh L, Stole M, Theuer D, Scheurlen C, et al. Double-blind dose-finding study of olsalazine versus sulphasalazine as maintenance therapy for ulcerative colitis. European Journal of Gastroenterology and Hepatology 1995;7:391-6. x-wiley/crsRef/14401988
51. Kruis W, Judmaier G, Kayasseh L, Stolte M, Scheurlen C, Hentschel E, et al. Double-blind dose-finding study of olsalazine vs. sulfasalazine for maintenance therapy of ulcerative colitis. Gastroenterology 1992;102:A649. x-wiley/crsRef/14401989
52. Kruis W, Stolte M. A double-blind dose finding study of olsalazine for the maintenance treatment of quiescent ulcerative colitis. Gastroenterology 1991;100(5 Part 2):A222. x-wiley/crsRef/14401990
53. Kruis W, Schreiber S, Theuer D, Brandes JW, Schutz E, Howaldt S, et al. Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapses. Gut 2001;49(6):783-9. x-wiley/crsRef/14401992
54. Kruis W, Greinwald R, Mueller R. Optimal dosing of mesalamine for maintenance of clinical remission in patients with distal ulcerative colitis and residual endoscopic activity: a subgroup analysis of a double-blind, double-dummy, randomized, controlled, dose-ranging study. Gastroenterology 2013;144(5 Suppl 1):S768. x-wiley/crsRef/14401994
55. Kruis W, Jonaitis L, Pokrotnieks J, Acute G, Mikhailova TL, Horynski M, et al. Once Daily 3g mesalamine is the optimal dose for maintaining clinical remission in ulcerative colitis: a double-blind, double-dummy, randomized, controlled, dose-ranging study. Gastroenterology 2008;134(4 Suppl 1):A489. x-wiley/crsRef/14401995
56. Kruis W, Jonaitis L, Pokrotnieks J, Mikhailova TL, Horynski M, Bátovský M, et al. Randomised clinical trial: a comparative dose-finding study of three arms of dual release mesalazine for maintaining remission in ulcerative colitis. Alimentary Pharmacology and Therapeutics 2011;33(3):313-22. x-wiley/crsRef/14401996
57. Lichtenstein GR, Gordon GL, Zakko S, Murthy U, Sedghi S, Pruitt R, et al. Clinical trial: once-daily mesalamine granules for maintenance of remission of ulcerative colitis – a 6-month placebo-controlled trial. Alimentary Pharmacology and Therapeutics 2010;32(8):990-9. x-wiley/crsRef/14401998
58. Mahmud N, O'Toole D, O'Hare N, Freyne PJ, Weir DG, Kelleher D. Evaluation of renal function following treatment with 5-aminosalicylic acid derivatives in patients with ulcerative colitis. Alimentary Pharmacology and Therapeutics 2002;16(2):207-15. x-wiley/crsRef/14402000
59. McIntyre PB, Rodrigues CA, Lennard-Jones JE, Barrison IG, Walker JG, Baron JH. Double blind controlled comparison of balsalazide and sulphasalazine in maintenance therapy of patients with ulcerative colitis [abstract]. Gut 1986;27:A1271. x-wiley/crsRef/14402002
60. McIntyre PB, Rodrigues CA, Lennard-Jones JE, Barrison IG, Walker JG, Baton JH, et al. Balsalazine in the maintenance treatment of patients with ulcerative colitis, a double-blind comparison with sulphasalazine. Alimentary Pharmacology and Therapeutics 1988;2:237-43. x-wiley/crsRef/14402003
61. Miner P, Hanauer S, Robinson M, Schwartz J, Arora S, Pentasa UC Maintenance Study Group. Safety and efficacy of controlled-release mesalamine for maintenance of remission in ulcerative colitis. Digestive Diseases and Sciences 1995;40:296-304. x-wiley/crsRef/14402005
62. Miner P, Schwartz J, Aora S, Robinson M, Hanauer S, the Pentasa Study Group. Maintenance of remission in ulcerative colitis (UC) patients with controlled-release mesalamine capsules (Pentasa). Gastroenterology 1992;102:A666. x-wiley/crsRef/14402006
63. Mulder CJ, Tytgat GN, Weterman IT, Dekker W, Blok P, Schrijver M, et al. Double-blind comparison of slow-release 5-aminosalicylate and sulfasalazine in remission maintenance in ulcerative colitis. Gastroenterology 1988;95:1449-53. x-wiley/crsRef/14402008
64. Mulder CJ, Tytgat GN, Weterman IT. Double blind evaluation of slow-release 5-aminosalicylic acid (Pentasa) and salazopyridin (Salazopyrin) in the maintenance therapy of ulcerative colitis. Gastroenterology 1988;94(5 Part 2):A313. x-wiley/crsRef/14402009
65. Nilsson A, Danielsson A, Lofberg R, Benno P, Bergman L, Fausa O, et al. Olsalazine versus sulphasalazine for relapse prevention in ulcerative colitis: a multicenter study. American Journal of Gastroenterology 1995;90:381-7. x-wiley/crsRef/14402011
66. Paoluzi OA, Iacopini F, Pica R, Crispino P, Marcheggiano A, Consolazio A, et al. Comparison of two different daily dosages (2.4 vs. 1.2 g) of oral mesalazine in maintenance of remission in ulcerative colitis patients: 1-year follow-up study. Alimentary Pharmacology and Therapeutics 2005;21(9):1111-9. x-wiley/crsRef/14402013
67. Paoluzi OA, Pica R, Crispino P, Iacopini F, Consolazio A, Rivera M, et al. Doubling daily dosage of oral mesalazine (2.4 vs. 1.2 g) in the maintenance therapy of pts with ulcerative colitis delays but does not reduce incidence of relapses: a 1-year follow-up study. Gastroenterology 2005;128(4 Suppl 2):A585. x-wiley/crsRef/14402014
68. Park SK, Eun CS, Seo GS, Lim J, Kim TO, Park DI. The effects and adherence of Asacol comparing 2.4 g once daily with 800 mg three times or 1200 mg twice daily for maintain therapy in the ulcerative colitis: prospective multicentre randomised study. Journal of Crohn's & Colitis 2018;12(Suppl 1):S367. x-wiley/crsRef/14402016
69. Park SK, Park SH, Eun CS, Seo GS, Im JP, Kim TO, et al. Adherence to Asacol once daily versus divided regimen for maintenance therapy in ulcerative colitis: a prospective, multicenter, randomized study. Intestinal Research 2019;17(3):349-56. x-wiley/crsRef/14402017
70. Pica R, Cassieri C, Cocco A, Marcheggiano A, Occhigrossi G, Zippi M, et al. Randomised open label trial comparing two different dosages of oral mesalazine in the maintenance treatment of ulcerative colitis. Italian Journal of Medicine 2012;1:108. x-wiley/crsRef/14402019
71. Kohn A, Prantera C, Caprilli R, Campieri M, Cottone M, Pallone F, et al. Maintenance treatment of ulcerative colitis with 5-aminosalicylic acid (5-ASA): results from the Italian population of a one year, randomized, multinational study comparing MMx® with Asacol®. Gastroenterology 2009;136(5 Suppl 1):390. x-wiley/crsRef/14402021
72. Prantera C, Kohn A, Campieri M, Caprilli R, Cottone M, Pallone F, et al. Clinical trial: ulcerative colitis maintenance treatment with 5-ASA: a 1-year, randomized multicentre study comparing MMX with Asacol. Alimentary Pharmacology and Therapeutics 2009;30(9):908-18. x-wiley/crsRef/14402022
73. Rijk MC, Lier HJ, Tongerson JH. Relapse-preventing effect and safety of sulfasalazine and olsalazine in patients with ulcerative colitis in remission: prospective, double-blind, randomized multicenter study. American Journal of Gastroenterology 1992;87:438-42. x-wiley/crsRef/14402024
74. Rijk MC, van Tongersen JH. The relapse preventing effect and safety of sulphasalazine and olsalazine in patients with ulcerative colitis in remission. Gastroenterology 1991;100(5 Part 2):A243. x-wiley/crsRef/14402025
75. Riley SA, Mani V, Goodman MJ, Herd ME, Dutt S, Turnberg LA. Comparison of delayed release 5 aminosalicylic acid (mesalazine) and sulfasalazine as maintenance treatment of patients with ulcerative colitis. Gastroenterology 2012;29(5):669-74. x-wiley/crsRef/14402027
76. Riley SA, Mani V, Goodman MJ, Herd ME, Dutt S, Turnberg LA. Comparison of delayed-release 5-aminosalicylic acid (mesalazine) and sulfasalazine as maintenance treatment for patients with ulcerative colitis. Gastroenterology 1988;94:1383-9. x-wiley/crsRef/14402028
77. Riley SA, Mani V, Goodman MJ, Turnberg LA. A comparison of delayed-release 5-ASA and sulfasalazine as maintenance treatment in ulcerative colitis. Gastroenterology 1987;92:A1596. x-wiley/crsRef/14402029
78. Riley SA, Mani V, Goodman MJ, Turnberg LA. A comparison of delayed-release 5-aminosalicylic acid (5-ASA) and sulfasalazine (SSZ) as maintenance treatment of ulcerative colitis (UC). Gut 1987;28:1390. x-wiley/crsRef/14402030
79. Rutgeerts P. Comparative efficacy of coated, oral 5-aminosalicylic acid (Claversal) and sulphasalazine for maintaining remission of ulcerative colitis. Alimentary Pharmacology and Therapeutics 1989;3:183-91. x-wiley/crsRef/14402031
80. Jarnerot G, Sandberg-Gertzen H. Azodisal sodium, (ADS), Dipentum, as relapse prevention in ulcerative colitis (UC). A double-blind placebo controlled study. Gastroenterology 1985;88(5 Part 2):A1432. x-wiley/crsRef/14402033
81. Sandberg-Gertzen H, Jarnerot G, Kraaz W. Azodisal sodium in the treatment of ulcerative colitis: a study of tolerance and relapse prevention properties. Gastroenterology 1986;90:1024-30. x-wiley/crsRef/14402034
82. Sandborn W, Kane S, Korzenik J, Lashner B, Leighton J, Mahadevan U, et al. Once daily dosing of delayed-release oral mesalamine for maintenance of remission of ulcerative colitis (the QDIEM trial): 6 and 12 month results. Inflammatory Bowel Diseases 2009;15:S15. x-wiley/crsRef/14402036
83. Sandborn WJ, Korzenik J, Lashner B, Leighton JA, Mahadevan U, Marion JF, et al. Once-daily dosing of delayed-release oral mesalamine (400-mg tablet) is as effective as twice-daily dosing for maintenance of remission of ulcerative colitis. Gastroenterology 2010;138(4):1286-96. x-wiley/crsRef/14402037
84. Suzuki Y, lida M, Ito H, Nishino H, Ohmori T, Arai T, et al. 2.4g Mesalamine (Asacol 400mg tablet) once daily is as effective as three times daily in maintenance of remission in ulcerative colitis: a randomized, noninferiority, multi-center trial. Inflammatory Bowel Diseases 2017;23(5):822-32. x-wiley/crsRef/14402039
85. Travis SP, Tysk C, de Silva HJ, Sandberg-Gertzen H, Jewell DP, Jarnerot G. Optimum dose of olsalazine for maintaining remission in ulcerative colitis. Gut 1994;35:1282-6. x-wiley/crsRef/14402041
86. Watanabe M, Hanai H, Nishino H, Yokoyama T, Terada T, Suzuki Y. Comparison of QD and TID oral mesalazine for maintenance of remission in quiescent ulcerative colitis: a double-blind, double-dummy, randomized multicenter study. Inflammatory Bowel Diseases 2013;19(8):1681-90. x-wiley/crsRef/14402043
87. Wright JP, O'Keefe EA, Cuming L, Jaskiewicz K. Olsalazine in maintenance of clinical remission in patients with ulcerative colitis. Digestive Diseases and Sciences 1993;38:1837-42. x-wiley/crsRef/14402045
88. Wright JP, O'Keefe EA, Cuming L, Jaskiewicz K. Olsalazine in the maintenance of remission in patients with ulcerative colitis. Gastroenterology 1992;102:A714. x-wiley/crsRef/14402046
89. Andreoli A, Spinella S, Levenstein S, Prantera C. 5-ASA enema versus oral sulphasalazine in maintaining remission in ulcerative colitis. Italian Journal of Gastroenterology 1994;26(3):121-5. x-wiley/crsRef/14402048
90. Bardazzi G, d'Albasio G, Bonanomi AG, Trallori G, Messori A, Amorosi A, et al. Intermittent versus continuous 5-aminosalicylic acid treatment for maintaining remission in ulcerative colitis. Italian Journal of Gastroenterology 1994;26(7):334-7. x-wiley/crsRef/14402049
91. d'Albasio G, Pacini F, Camarri E, Messori A, Trallori G, Bonanomi AG, et al. Combined therapy with 5-aminosalicylic acid tablets and enemas for maintaining remission in ulcerative colitis: a randomized double-blind study. American Journal of Gastroenterology 1997;92(7):1143-7. x-wiley/crsRef/14402050
92. D'Haens GR, Sandborn WJ, Zou G, Stitt LW, Rutgeerts PJ, Gilgen D, et al. Randomised non-inferiority trial: 1600 mg versus 400 mg tablets of mesalazine for the treatment of mild-to-moderate ulcerative colitis. Alimentary Pharmacology & Therapeutics 2017;46(3):292-302. x-wiley/crsRef/14402052
93. Dew MJ, Hughes P, Harries AD, Williams G, Evans BK, Rhodes J. Maintenance of remissions in ulcerative colitis with oral preparation of 5-aminosalicylic acid. British Medical Journal 1982;285:1012. x-wiley/crsRef/14402053
94. Dignass A, Bokemeyer B, Stijnen T, Tan T, Borner N, Oudkerk Pool M, et al. Safety of once-daily vs twice-daily mesalazine (Pentasa) dosing. Results from a 12-month randomised controlled trial in maintenance of remission of ulcerative colitis. In: Canadian Journal of Gastroenterology. Vol. 23. 2009. x-wiley/crsRef/14402055
95. Dignass A, Schnabel R, Romatowski J, Pavlenko V, Dorofeyev A, Derova J. Efficacy and safety of a novel high-dose mesalazine tablet in mild to moderate active ulcerative colitis: a double-blind, multicentre, randomised trial. United European Gastroenterology Journal 2018;6(1):138-47. x-wiley/crsRef/14402057
96. Eliakim R, Wengrower D, Ligumsky M, Rachmilewitz D. Comparable efficacy of oral 5-ASA (Mesasal) and sulfasalazine in maintaining ulcerative colitis in remission. Israel Journal of Medical Sciences 1990;26(1):47-9. x-wiley/crsRef/14402058
97. Ewe K, Becker K, Ueberschaer B. Systemic uptake of 5-aminosalicylic acid from olsalazine and Eudragit L coated mesalazine in patients with ulcerative colitis in remission. Zeitschrift fur Gastroenterologie 1996;34(4):225-9. x-wiley/crsRef/14402059
98. Fernández-Bañares F, Hinojosa J, Sánchez-Lombraña JL, Navarro E, Martínez-Salmerón JF, García-Pugés A, et al. Randomized clinical trial of Plantago ovata seeds (dietary fiber) as compared with mesalamine in maintaining remission in ulcerative colitis. American Journal of Gastroenterology 1999;94(2):427-33. x-wiley/crsRef/14402060
99. Frieri G, Pimpo M, Galletti B, Palumbo G, Corrao G, Latella G, et al. Long-term oral plus topical mesalazine in frequently relapsing ulcerative colitis. Digestive and Liver Disease 2005;37(2):92-6. x-wiley/crsRef/14402061
100. Giaffer MH, O'Brien CJ, Holdsworth CD. Clinical tolerance to three 5-aminosalicylic acid releasing preparations in patients with inflammatory bowel disease intolerant or allergic to sulphasalazine. Alimentary Pharmacology and Therapeutics 1992;6(1):51-9. x-wiley/crsRef/14402062
101. Gillespie D, Hood K, Farewell D, Stenson R, Probert C, Hawthorne AB. Electronic monitoring of medication adherence in a 1-year clinical study of 2 dosing regimens of mesalazine for adults in remission with ulcerative colitis. Inflammatory Bowel Diseases 2014;20(1):82-91. x-wiley/crsRef/14402064
102. Gionchetti P, Campieri M, Belluzzi A, Brignola C, Tampieri M, Iannone P, et al. Pentasa in maintenance treatment of ulcerative colitis. Gastroenterology 1990;98:251. x-wiley/crsRef/14402065
103. Gionchetti P, Campieri M, Venturi A, Rizzello F, Ferretti M, Brignola C, et al. Systemic availability of 5-aminosalicylic acid: comparison of delayed release and an azo-bond preparation. Alimentary Pharmacology and Therapeutics 1996;10(4):601-5. x-wiley/crsRef/14402066
104. Green JR, Swan CH, Gibson JA, Kerr GD, Swarbrick ET, Thornton PC. Patient-led variable dosing with balsalazide as long-term therapy for maintenance in ulcerative colitis: a 3-year prospective observational study. Alimentary Pharmacology and Therapeutics 2004;19(4):435-42. x-wiley/crsRef/14402067
105. Hanauer SB, Lichtenstein GR, Kamm MA, Sandborn WJ, Lees KH, Barrett K, et al. MMX mesalamine for induction and maintenance therapy in mild-to-moderate ulcerative colitis. Gastroenterology and Hepatology 2009;5(7):494-500. x-wiley/crsRef/14402068
106. Karamanolis DG, Papatheodoridis GV, Xourgias V. Systemic absorption of 5-aminosalicylic acid in patients with inactive ulcerative colitis treated with olsalazine and mesalazine. European Journal of Gastroenterology and Hepatology 1996;8(11):1083-8. x-wiley/crsRef/14402069
107. Kruis W, Schütz E, Fric P, Fixa B, Judmaier G, Stolte M. Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Alimentary Pharmacology and Therapeutics 1997;11(5):853-8. x-wiley/crsRef/14402070
108. Kruis W, Fric P, Pokrotnieks J, Lukas M, Fixa B, Kascak M, et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut 2004;53(11):1617-23. x-wiley/crsRef/14402071
109. Levine A, Yerushalmi B, Kori M, Broide E, Mozer-Glassberg Y, Shaoul R, et al. Mesalamine enemas for induction of remission in pediatric ulcerative colitis refractory to oral mesalamine: a prospective cohort study. Journal of Crohn's & Colitis 2017;11(Suppl 1):S285. x-wiley/crsRef/14402073
110. Levine A, Yerushalmi B, Kori M, Broide E, Mozer-Glassberg Y, Shaoul R. Mesalamine enemas for induction of remission in pediatric ulcerative colitis refractory to oral Mesalamine: a prospective cohort study. Journal of Pediatric Gastroenterology and Nutrition 2017;64(Suppl 1):49. x-wiley/crsRef/14402074
111. Mani V, Gotch P. Comparison of pharmacokinetics and colonic transit time in quiescent ulcerative colitis on mesalazine and olsalazine – a cross over study. Gut 1994;35(Suppl 4):A124. x-wiley/crsRef/14402075
112. Mantzaris GJ, Sfakianakis M, Archavlis E, Petraki K, Christidou A, Karagiannidis A, et al. A prospective randomized observer-blind 2-year trial of azathioprine monotherapy versus azathioprine and olsalazine for the maintenance of remission of steroid-dependent ulcerative colitis. American Journal of Gastroenterology 2004;99(6):1122-8. x-wiley/crsRef/14402076
113. Odes HS. 5-Aminosalicylic acid, 1,000-mg caplets versus 500-mg tablets, in maintenance of remission in ulcerative colitis. Journal of Clinical Gastroenterology 1997;24(4):287-8. x-wiley/crsRef/14402077
114. Osterman MT, Aberra F, Cross R, Liakos S, McCabe RP, Shafran I, et al. A randomized controlled trial of mesalamine dose escalation for ulcerative colitis in remission. Gastroenterology 2014;146(5 Suppl 1):S149. x-wiley/crsRef/14402078
115. Paoluzi P, D'Albasio G, Pera A, Bianchi Porro G, Paoluzi OA, Pica R, et al. Oral and topical 5-aminosalicylic acid (mesalazine) in inducing and maintaining remission in mild-moderate relapse of ulcerative colitis: one-year randomised multicentre trial. Digestive and Liver Disease 2002;34(11):787-93. x-wiley/crsRef/14402079
116. Papatheodoridis GV, Xourgias V, Sdonas T, Triantoafyllou M, Tzouvaia M, Karamanolis DG. Systematic load of 5-ASA in patients with inactive ulcerative colitis treated with olsalazine and mesalazine. Gut 1995;37(Suppl 2 Pt 2):A54. x-wiley/crsRef/14402080
117. Pelech T, Fric P, Fixa B, Komarkova O. Comparison of Mutaflor and mesalazine in the maintenance treatment of inactive ulcerative colitis. Prakticky Lekar 1998;78(10):556-8. x-wiley/crsRef/14402081
118. Pica R, Cassieri C, Cocco A, Zippi M, Marcheggiano A, De Nitto D, et al. A randomized trial comparing 4.8 vs. 2.4 g/day of oral mesalazine for maintenance of remission in ulcerative colitis. Digestive & Liver Disease 2015;47(11):933-7. x-wiley/crsRef/14402083
119. Rubin DT, Cohen RD, Sandborn WJ, Lichtenstein GR, Axler J, Riddell RH, et al. Budesonide multimatrix is efficacious for mesalamine-refractory, mild to moderate ulcerative colitis: a randomised, placebo-controlled trial. Journal of Crohn's & Colitis 2017;11(7):785-91. x-wiley/crsRef/14402085
120. Scherl E, Pruitt R, Sedghi S, Barrett A, Bortey E, Paterson C, et al. Long-term safety and tolerability of twice-daily balsalazide disodium tablets in patients with ulcerative colitis. American Journal of Gastroenterology 2013;108:S545. x-wiley/crsRef/14402087
121. Staerk Laursen L, Stokholm M, Bukhave K, Rask-Madsen J, Lauritsen K. Disposition of 5-aminosalicylic acid by olsalazine and three mesalazine preparations in patients with ulcerative colitis: comparison of intraluminal colonic concentrations, serum values, and urinary excretion. Gut 1990;31:1271-6. x-wiley/crsRef/14402088
122. Florholmen J. The systemic load and efficient delivery of active 5-ASA in patients with ulcerative colitis on treatment with Dipentum (olsalazine) and Mesasael (mesalazine). Gut 1994;35(Suppl 4):A121. x-wiley/crsRef/14402089
123. Stoa-Birketvedt G, Florholmen J. The systemic load and efficient delivery of active 5-aminosalicylic acid in patients with ulcerative colitis on treatment with olsalazine or mesalazine. Alimentary Pharmacology and Therapeutics 1999;13:357-61. x-wiley/crsRef/14402090
124. Sun J, Yuan Y. Mesalazine modified-release tablet in the treatment of ulcerative colitis in the remission phase: a Chinese, multicenter, single-blind, randomized controlled study. Advances in Therapy 2016;33(3):410-22. x-wiley/crsRef/14402092
125. Tragnone A, Elmi G, Tagliente C, Bazzocchi G, Dina R, Euseb V, et al. Oral 5-aminosalicylic acid therapy for the prevention of relapse in patients with ulcerative colitis (UC) during remission: a new therapeutical approach by using 5-ASA tablets 800 mg. A multicenter controlled randomized trial. Gastroenterology 1996;110:A1030. x-wiley/crsRef/14402093
126. Turner D, Yerushalmi B, Kori M, Broide E, Mozer-Glassberg Y, Shaoul R, et al. Once- versus twice-daily mesalazine to induce remission in paediatric ulcerative colitis: a randomised controlled trial. Journal of Crohn's & Colitis 2017;11(5):527-33. x-wiley/crsRef/14402095
127. Archimandritis A, Hatzis G, Konstandinidis A, Paraskeva K, Tjivras M, Skandalis N. Disposition of 5-ASA by olsalazine (Dipentum) and mesalazine (Asacol) in patients with ulcerative colitis in remission. Gut 1996;39(Suppl 3):A75. x-wiley/crsRef/14402096
128. Tzivras M, Konstandinidis A, Hatzis G, Paraskeva K, Skandalis N, Archimandritis A. Systemic absorption of 5-aminosalicylic acid in patients with inactive ulcerative colitis treated with olsalazine and mesalazine. European Journal of Gastroenterology and Hepatology 1997;9(7):729-30. x-wiley/crsRef/14402097
129. Yokoyama H, Takagi S, Kuriyama S, Takahashi S, Takahashi H, Iwabuchi M, et al. Effect of weekend 5-aminosalicylic acid (mesalazine) enema as maintenance therapy for ulcerative colitis: results from a randomized controlled study. Inflammatory Bowel Diseases 2007;13(9):1115-20. x-wiley/crsRef/14402098
130. Zocco MA, Dal Verme LZ, Cremonini F, Piscaglia AC, Nista EC, Candelli M, et al. Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis. Alimentary Pharmacology and Therapeutics 2006;23:1567-74. x-wiley/crsRef/14402099
131. NCT02280629. Phosphatidylcholine (LT-02) vs. placebo vs. mesalamine for maintenance of remission in ulcerative colitis (PROTECT-2) [Randomized, double-blind, double-dummy, placebo-controlled, phase III clinical trial on the efficacy and safety of a 48-weeks treatment with gastro-resistant phosphatidylcholine (LT-02) versus placebo versus mesalamine for maintenance of remission in patients with ulcerative colitis]. clinicaltrials.gov/show/NCT02280629 (first received 31 October 2014). x-wiley/crsRef/14402101
132. NCT02522780. Mesalamine 2 g Sachet for the maintenance of clinical and endoscopic remission in ulcerative colitis (UC) [A randomized, double-blind, placebo-controlled, multicenter study investigating the efficacy and safety of mesalamine 2 g extended release granules (Sachet) for maintenance of clinical and endoscopic remission in ulcerative colitis]. clinicaltrials.gov/show/NCT02522780 (first received 13 August 2015). x-wiley/crsRef/14402103
133. Andrade SE, Walker AM, Gottlieb LK, Hollenberg NK, Testa MA, Saperia GM, et al. Discontinuation of antihyperlipidemic drugs – do rates reported in clinical trials reflect rates in primary care settings? New England Journal of Medicine 1995;332(17):1125-31.
134. Azad Khan AK, Piris J, Truelove SC. An experiment to determine the active therapeutic moiety of sulfasalazine. Lancet 1977;2(8044):892-5.
135. Beaulieu DB Schwartz DA. Medication persistence in patients with ulcerative colitis: meeting the challenges and improving patient outcomes CME. MedScape CME Gastroenterology Posted 22 December 2009.
136. Brixner D, Magowan S, Accortt N. Evaluation of prescription refill patterns based on daily dosing regimen and pill load for calcium channel blockers. Academy of Managed Care Pharmacy 19th Annual Meeting; 2007 Apr 10–13; San Diego (CA), 2007.
137. Chan RP, Pope DJ, Gilbert AP, Sacra PJ, Baron JH, Lennard-Jones JE. Studies of two novel sulfasalazine analogs, ipsalazide and balsalazide. Digestive Diseases and Sciences 1983;28:609-15.
138. Danese S, Fiocchi C. Ulcerative colitis. New England Journal of Medicine 2011;365(18):1713-25.
139. Das KM, Eastwood MA, McManus JP, Sircus W. Adverse reactions during salicylazosulfapyridine therapy and the relation with drug metabolism and acetylator phenotype. New England Journal of Medicine 1973;289:491-5.
140. Dew MJ, Hughes PJ, Lee MG, Evans BK, Rhodes J. An oral preparation to release drugs in the human colon. British Journal of Clinical Pharmacology 1982;14:405-8.
141. Ediger JP, Walker JR, Graff L, Lix L, Clara I, Rawsthorne P, et al. Predictors of medication adherence in inflammatory bowel disease. American Journal of Gastroenterology 2007;102(7):1417-26.
142. Feuerstein JD, Cheifetz AS. Ulcerative colitis. Mayo Clinic Proceedings 2014;89(11):1553-63.
143. Fleig WE, Laudage G, Sommer H, Wellmann W, Stange EF, Riemann J. Prospective, randomized, double-blind comparison of benzalazine and sulfasalazine in the treatment of active ulcerative colitis. Digestion 1988;40(3):173-80.
144. Ford AC, Achkar JP, Khan KJ, Kane SV, Talley NJ, Marshall JK, et al. Efficacy of 5-aminosalicylates in ulcerative colitis: systematic review and meta-analysis. American Journal of Gastroenterology 2011;106:601-16.
145. Ford AC, Khan KJ, Sandborn WJ, Kane SV, Moayyedi P. Once-daily dosing vs. conventional dosing schedule of mesalamine and relapse of quiescent ulcerative colitis: systematic review and meta-analysis. American Journal of Gastroenterology 2011;106:2070-7.
146. Greenfield SM, Punchard NA, Teare JP, Thompson RP. Review article: the mode of action of the aminosalicylates in inflammatory bowel disease. Alimentary Pharmacology and Therapeutics 1993;7:369-83.
147. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336(7650):924-6.
148. Hardy JG, Healey JN, Reynolds JR. Evaluation of an enteric-coated delayed-release 5-aminosalicylic acid tablet in patients with inflammatory bowel disease. Alimentary Pharmacology and Therapeutics 1987;1:273-80.
149. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analysis. BMJ 2003;327:557-60.
150. Higgins JP, Altman DG, Sterne JA. Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
151. Higgins JP, Deeks JJ, Altman DG. Chapter 16: Special topics in statistics. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
152. Ireland A, Jewell DP. Olsalazine in patients intolerant of sulfasalazine. Scandinavian Journal of Gastroenterology 1988;23(Suppl 148):101-3.
153. Jarnerot G. Withdrawal rates because of diarrhoea in Dipentum-treated patients with ulcerative colitis are low when Dipentum is taken with food and dose titrated [abstract]. Gastroenterology 1996;110:A932.
154. Kane SV, Cohen RD, Aikens JE, Hanauer SB. Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis. American Journal of Gastroenterology 2001;96(10):2929-33.
155. Kane S, Huo D, Aikens J, Hanauer S. Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. American Journal of Medicine 2003;114(1):39-43.
156. Kane SV. Systematic review: adherence issues in the treatment of ulcerative colitis. Alimentary Pharmacology and Therapeutics 2006;23(5):577-85.
157. Kane SV, Brixner D, Rubin DT, Sewitch MJ. The challenge of compliance and persistence: focus on ulcerative colitis. Journal of Managed Care Pharmacy 2008;14(1 Suppl A):S2-12.
158. Kjaergaard N, Ambrosius Christensen L, Lauritsen JG, Rasmussen N, Honore Hansen S. Effects of mesalazine substitution on salicylazosulfapyridine-induced seminal abnormalities in men with ulcerative colitis. Scandinavian Journal of Gastroenterology 1989;24:891-6.
159. Klotz U, Maier K, Fischer C, Heinkel K. Therapeutic efficacy of sulfasalazine and its metabolites in patients with ulcerative colitis and Crohn's disease. New England Journal of Medicine 1980;303:1499-502.
160. Levy RL, Feld AD. Increasing patient adherence to gastroenterology treatment and prevention regimens. American Journal of Gastroenterology 1999;94(7):1733-42.
161. Loftus EJ. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology 2004;126(6):1504-17.
162. Magowan S, Kane S, Lange JL. 5-ASA prescription refill rates for ulcerative colitis are independent of formulation and dosing regimens. American Journal of Gastroenterology 2006;101:S447.
163. Misiewitz JJ, Lennard-Jones JE, Connell AM, Baron JH, Jones FA. Controlled trial of sulfasalazine in maintenance therapy for ulcerative colitis. Lancet 1965;1:185-8.
164. Myers B, Evans DN, Rhodes J, Evans BK, Hughes BR, Lee MG, et al. Metabolism and urinary excretion of 5-aminosalicylic acid in healthy volunteers when given intravenously or released for absorption at different sites in the gastrointestinal tract. Gut 1987;28:196-200.
165. Nielsen OH. Sulfasalazine intolerance: a retrospective study of the reasons for discontinuing treatment with sulfasalazine in patients with chronic inflammatory bowel disease. Scandinavian Journal of Gastroenterology 1982;17:389-93.
166. Nielsen OH, Bondesen S. Kinetics of 5-aminosalicylic acid after jejunal instillation in man. British Journal of Clinical Pharmacology 1983;16:738-40.
167. Peppercorn MA, Goldman P. The role of intestinal bacteria in the metabolism of salicylazo-sulfapyridine. Journal of Pharmacology and Experimental Therapeutics 1972;181:555-62.
168. Rao SS, Cann PA, Holdsworth CD. Clinical experience of the tolerance of mesalazine and olsalazine in patients intolerant of sulfasalazine. Scandinavian Journal of Gastroenterology 1987;22:332-6.
169. Rasmussen SN, Bondesen S, Hvidberg EF, Hansen SH, Binder V, Halskou S, et al. 5-aminosalicylic acid in a slow-release preparation: bioavailability, plasma level, and excretion in humans. Gastroenterology 1982;83:1062-70.
170. Nordic Cochrane Centre, The Cochrane Collaboration Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
171. Riley SA, Lecarpentier J, Mini V, Goodman JJ, Mandal BK, Turnberg LA. Sulfasalazine induced seminal abnormalities in ulcerative colitis: result of mesalazine substitution. Gut 1987;28:1008-12.
172. Rothfuss KS, Stange EF, Herrlinger KR. Extraintestinal manifestations and complications in inflammatory bowel diseases. World Journal of Gastroenterology 2006;12(30):4819-31.
173. Sandborn WJ. Rational selection of oral 5-aminosalicylate formulations and prodrugs for the treatment of ulcerative colitis. American Journal of Gastroenterology 2002;97(12):2939-41.
174. Sandborn WJ, Hanauer SB, Buch A. Comparable systemic absorption of 5-ASA and N-AC-5-ASA from U.S. Asacol and Colazal. American Journal of Gastroenterology 2002;97:S263.
175. Sandborn WJ, Hanauer SB. The pharmacokinetic profiles of oral 5ASA formulations used in the management of ulcerative colitis: a systematic review. American Journal of Gastroenterology 2002;97:S269.
176. Sandborn WJ, Hanauer SB. Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis. Alimentary Pharmacology and Therapeutics 2003;17(1):29-42.
177. Schroeder H, Campbell DE. Absorption, metabolism, and excretion of salicylazosulfapyridine in man. Clinical Pharmacology and Therapeutics 1972;13:539-51.
178. Schünemann HJ, Oxman AD, Vist GE, Higgins JP, Deeks JJ, Glasziou P, et al. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
179. Shale MJ, Riley SA. Studies of compliance with delayed-release mesalazine therapy in patients with inflammatory bowel disease. Alimentary Pharmacology and Therapeutics 2003;18(2):191-8.
180. Svartz N. Salazopyrin, a new sulfanilamide preparation: A. Therapeutic results in rheumatic polyarthritis. B. Therapeutic results in ulcerative colitis. C. Toxic manifestations in treatment with sulfanilamide preparation. Acta Medica Scandinavica 1942;110:557-90.
181. Truelove SC, Witts LJ. Cortisone in ulcerative colitis: final report on a therapeutic trial. British Medical Journal 1955;4947:1041-8.
182. Truelove SC, Witts LJ. Cortisone and corticotrophin in ulcerative colitis. British Medical Journal 1959;i:387-94.
183. Van Hees PA, Bakker JH, Tongeren JH. Effect of sulfapyridine, 5-aminosalicylic acid, and placebo in patients with idiopathic proctitis: a study to determine the active therapeutic moiety of sulfasalazine. Gut 1980;21:632-5.
184. Willoughby CP, Aronson JK, Agback H, Bodin NO, Truelove SC. Distribution and metabolism in healthy volunteers of disodium azodisalicylate, a potential therapeutic agent for ulcerative colitis. Gut 1982;23:1081-7.
185. Feagan BG, MacDonald JK. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database of Systematic Reviews 2012, Issue 10. Art. No: CD000544. [DOI: 10.1002/14651858.CD000544.pub3]
186. Sutherland LR, May GR, Shaffer EA. Sulfasalazine revisited: a meta-analysis of 5-aminosalicylic acid in the treatment of ulcerative colitis. Annals of Internal Medicine 1993;118:540-9.
187. Sutherland LR, Roth DE, Beck PL. Alternatives to sulfasalazine: A meta-analysis of 5-ASA in the treatment of ulcerative colitis. Inflammatory Bowel Diseases 1997;3:65-78.
188. Sutherland LR, MacDonald JK. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database of Systematic Reviews 2006, Issue 2. Art. No: CD000544. [DOI: 10.1002/14651858.CD000544.pub2]
189. Wang Y, Parker CE, Feagan BG, MacDonald JK. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database of Systematic Reviews 2016, Issue 5. Art. No: CD000544. [DOI: 10.1002/14651858.CD000544.pub4]